Trials / Completed
CompletedNCT00920725
Subcutaneous Aspart Insulin to Treat Diabetic Ketoacidosis (DKA) and Beta-Hydroxybutyrate Testing in DKA
Subcutaneous Aspart Insulin and Point of Care Beta Hydroxybutyrate Testing: A New Paradigm for the Management of Diabetic Ketoacidosis
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Rush University Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to determine whether insulin administered by a subcutaneous injection is effective in the treatment of a diabetic crisis and to determine if beta-hydroxybutyrate is useful to monitor during treatment of a diabetic crisis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Insulin (Aspart Insulin [Novolog], Regular Insulin) | Aspart Insulin 0.2units/sq q 2 hours Regular Insulin 0.1units/kg/hr intravenous Aspart Insulin 0.1 units/kg/hr intravenous |
Timeline
- Start date
- 2005-01-01
- Primary completion
- 2007-07-01
- Completion
- 2007-12-01
- First posted
- 2009-06-15
- Last updated
- 2012-08-16
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00920725. Inclusion in this directory is not an endorsement.